Table 4.
Overview of symptomatic and any ICH, and hemorrhagic transformation tendencies in cancer patients compared to non-cancer patients.
| Author, Year | sICH | Any ICH | HT |
|---|---|---|---|
| Cho et al., 2020 [10] | - | - | NA |
| Ciolli et al., 2021 [11] | - | - | NA |
| Jeon et al., 2021 [19] | ↑ * | ↑ * | NA |
| Joshi et al., 2022 [6] | NA | NA | ↑ |
| Lee et al., 2019 [13] | NA | ↑ | NA |
| Lee et al., 2021 [14] | NA | ↑ | - |
| Mattingly et al., 2022 [8] | NA | - | NA |
| Merlino et al., 2021 [15] | ↑/- | NA | NA |
| Murthy et al., 2013 [20] | NA | - | NA |
| Oki et al., 2020 [7] | NA | NA | ↑ * |
| Ozaki et al., 2021 [16] | - | NA | NA |
| Rinaldo et al., 2019 [22] | NA | - | NA |
| Sallustio et al., 2019 [17] | - | - | NA |
| Verschoof et al., 2022 [23] | - | NA | NA |
| Yoo et al., 2021 [18] | - | NA | - |
Note: -: No significant difference. ↑: Increased in cancer patients. NA: Not assessed/applicable.* Study did not compare CP and NCP, increased based on respective NCP metrics of other similar studies.